PureTech Health (LON:PRTC) Stock Crosses Above Fifty Day Moving Average – Here’s Why

PureTech Health plc (LON:PRTC)’s stock price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of GBX 122.01 and traded as high as GBX 127. PureTech Health shares last traded at GBX 126, with a volume of 1,577,197 shares trading hands.

Wall Street Analyst Weigh In

Separately, Peel Hunt reiterated a “buy” rating and issued a GBX 508 price target on shares of PureTech Health in a report on Monday, July 13th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, PureTech Health presently has an average rating of “Buy” and an average target price of GBX 508.

PureTech Health Stock Down 3.5%

The company has a market cap of £296.00 million, a P/E ratio of -2.64 and a beta of 0.77. The company has a debt-to-equity ratio of 6.33, a quick ratio of 2.51 and a current ratio of 6.59. The business’s fifty day moving average is GBX 121.82 and its two-hundred day moving average is GBX 124.46.

Insider Transactions at PureTech Health

In other news, insider Kiran Mazumdar Shaw acquired 93,944 shares of PureTech Health stock in a transaction on Wednesday, July 29th. The shares were bought at an average cost of GBX 1 per share, for a total transaction of £939.44. Also, insider Michele Holcomb bought 93,944 shares of the stock in a transaction on Wednesday, July 29th. The stock was purchased at an average price of GBX 1 per share, with a total value of £939.44. Insiders have bought 617,569 shares of company stock valued at $18,063,751 in the last ninety days. Corporate insiders own 13.41% of the company’s stock.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.